PT-141: Research and Use
A factual, evidence-based look at bremelanotide — the peptide that works on desire through the brain rather than blood flow, and one of the few with full FDA approval behind it.
This guide summarizes published research and regulatory data on PT-141 (bremelanotide). It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
PT-141 occupies an unusual position among research peptides. While most peptides discussed in the wellness space have promising but limited human data, PT-141 has been through the full clinical trial process and earned FDA approval. It's also one of the more scientifically interesting compounds in the field, because it addresses sexual desire through an entirely different route than the well-known erectile dysfunction medications — it works on the brain, not on blood flow.
This guide gives you an honest, evidence-based picture: what PT-141 is, how it actually works, what the clinical research shows for both women and men, the practical details of its use, and the genuine considerations to be aware of.
What PT-141 Is
PT-141, known generically as bremelanotide, is a synthetic cyclic heptapeptide — a chain of seven amino acids arranged in a closed ring. It's a structural analog of alpha-melanocyte-stimulating hormone (α-MSH), a hormone your body produces naturally that influences a range of processes including pigmentation, energy balance, and sexual function.
An Accidental Discovery
PT-141 has one of the more interesting origin stories in pharmacology. It was derived from an earlier compound called Melanotan II, which was being studied as a synthetic tanning agent. During that research, scientists noticed that Melanotan II consistently produced an unexpected side effect: increased sexual arousal in study participants. Researchers at Palatin Technologies isolated and refined that arousal-related activity into a cleaner, more targeted molecule — PT-141 — that preserved the effect on desire while removing the skin-darkening properties. A drug designed for one purpose revealed an entirely different mechanism.
How It Works
This is where PT-141 gets genuinely interesting, and where it differs most from what people expect. PT-141 works through the central nervous system — the brain — rather than through the circulatory system.
Specifically, it activates melanocortin receptors (primarily MC4R, and to a lesser extent MC3R) in regions of the hypothalamus involved in sexual motivation — the paraventricular nucleus and medial preoptic area. By engaging these receptors, PT-141 influences the dopamine-related pathways that govern sexual desire and arousal at their neurological source.
The practical meaning of this is important: PT-141 addresses desire itself, at the level of the brain, rather than the physical mechanics of arousal. This is fundamentally different from how the common erectile dysfunction drugs work, which we'll cover next.
An interesting note on duration
PT-141 has a relatively short half-life of around 2.7 hours, yet users often report effects lasting considerably longer. Researchers believe this is because engaging the brain's melanocortin receptors produces downstream neurological effects that outlast the actual presence of the peptide in the bloodstream — the signal sets off a cascade that continues after the peptide itself has cleared.
What Makes It Different From Viagra-Type Drugs
The most common point of confusion about PT-141 is assuming it works like sildenafil (Viagra) or tadalafil (Cialis). It doesn't — and understanding the difference is key to understanding what PT-141 is actually for.
| PT-141 (Bremelanotide) | PDE5 Inhibitors (Viagra, Cialis) | |
|---|---|---|
| Works on | The brain (desire pathways) | Blood vessels (blood flow) |
| Addresses | Desire and arousal | Physical mechanics of erection |
| Mechanism | Melanocortin receptor activation | Increased blood flow via PDE5 enzyme |
| Approved for | HSDD in premenopausal women | Erectile dysfunction in men |
The two approaches are complementary rather than competing. PDE5 inhibitors solve a "plumbing" problem — they help with the physical ability to achieve an erection but do nothing for desire. PT-141 works on desire and motivation at the brain level, addressing a problem the blood-flow drugs simply don't touch. This is why PT-141 is sometimes of interest to people for whom the conventional drugs don't fully address the issue — because low desire and physical mechanics are different problems.
FDA Approval & Research History
PT-141's regulatory history is one of its most distinguishing features. Unlike most research peptides, it has been scrutinized at the level of a fully approved pharmaceutical.
The Approval
In June 2019, the FDA approved bremelanotide under the brand name Vyleesi (developed by Palatin Technologies) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as a persistent lack of sexual desire that causes marked personal distress, and that isn't better explained by a medical condition, relationship issues, or medication side effects.
The Clinical Trials
Approval was based on two large Phase 3 randomized controlled trials known as RECONNECT, which together enrolled 1,267 premenopausal women with HSDD. These trials evaluated the now-standard 1.75 mg subcutaneous dose and established the efficacy and safety profile that supported FDA approval. The compound also had more than a decade of earlier development behind it, including Phase 2 work.
Why the approval matters
FDA approval means PT-141's pharmacology, safety profile, and dosing have been studied at a level very few research peptides ever reach. While the approved indication is specific (female HSDD), the underlying science — how the molecule behaves, its safety data, its dosing — rests on a much firmer foundation than most peptides on the market.
The Evidence for Women and Men
Being precise about what the research does and doesn't establish is important here, because it's an area where marketing often outpaces evidence.
For Women
This is the well-established use. The Phase 3 RECONNECT trials specifically studied premenopausal women with HSDD, and the FDA approval applies to this population. For these women, PT-141 has robust, regulatory-grade evidence behind it — the strongest evidence base of any peptide in the sexual health space.
For Men
PT-141 was actually first investigated for erectile dysfunction in men, and there is Phase 2 data supporting its use in male sexual dysfunction — including in some men who don't respond well to conventional PDE5 inhibitors. However, FDA approval for men was never formally pursued, in part because earlier intranasal formulations showed dose-dependent blood pressure increases that pushed development toward the narrower female indication. So for men, the evidence is genuinely promising but at the Phase 2 level rather than the full approval standard.
What the Evidence Does Not Establish
To be straightforward: there is no Phase 3 evidence supporting PT-141 use in men, in postmenopausal women, or via intranasal routes. Use outside the approved female HSDD protocol relies on Phase 2 data and clinical extrapolation. The pharmacology is well-characterized across the board, but the highest-grade human efficacy evidence specifically supports the female HSDD indication.
Dosing & Administration
The dosing information below reflects the FDA-approved Vyleesi label and published clinical trial protocols. These are informational references, not personal recommendations — any dosing decision should involve a qualified healthcare professional.
| Parameter | Per the Vyleesi Label / Trials |
|---|---|
| Standard dose | 1.75 mg subcutaneous |
| Timing | At least 45 minutes before anticipated sexual activity |
| Frequency | As-needed (PRN); not a daily medication |
| Maximum | No more than one dose per 24 hours; up to 8 doses per month per the label |
| Route | Subcutaneous injection (abdomen or thigh) |
An Important Difference From Other Peptides
Unlike most peptides — which are taken on a regular daily or weekly schedule for an ongoing effect — PT-141 is used on an as-needed basis, taken before anticipated activity rather than continuously. This "use when needed" pattern is more like how the conventional ED medications are used than how most research peptides work.
Reconstitution
Our PT-141 is supplied as a 10 mg lyophilized vial, reconstituted with bacteriostatic water before use. Because the per-use dose is small, a single vial provides multiple doses. For step-by-step preparation and injection technique, see our how to reconstitute peptides and dosing and injection basics guides. As with any peptide, starting at the lower end and assessing your response is the sensible approach.
Side Effects & Safety
Because PT-141 went through full clinical trials, its side effect profile is well-documented — better than most peptides.
Most Common Side Effect: Nausea
Nausea is by far the most commonly reported effect, affecting roughly 40% of women in the Phase 3 trials. It's usually most noticeable with the first few doses and tends to lessen with subsequent use. Taking it on a relatively empty stomach and starting with a conservative dose can help. For most people it's mild to moderate and manageable.
Other Reported Effects
- Flushing — warmth or redness, a known melanocortin-related effect
- Headache — reported, usually mild
- Injection site reactions — redness or minor irritation, common to all injectables
- Temporary blood pressure changes — PT-141 can cause a transient rise in blood pressure and a small drop in heart rate after dosing (covered below)
- Skin hyperpigmentation — with frequent or higher-than-label use, some darkening of skin (a reminder of its melanocortin/tanning-related origins) can occur, more likely with repeated dosing
⚠ The blood pressure consideration
PT-141 causes a temporary, transient increase in blood pressure (and a slight decrease in heart rate) in the hours after dosing. For most healthy people this is modest and short-lived, but it's the single most important reason PT-141 is not appropriate for people with uncontrolled high blood pressure or known cardiovascular disease. Anyone with heart or blood pressure concerns should not use PT-141 without clearance from a qualified healthcare professional. This is non-negotiable.
Who Should Avoid PT-141
- Anyone with uncontrolled high blood pressure or known cardiovascular disease
- Pregnant or breastfeeding women
- Anyone with significant heart conditions
- People taking medications that affect blood pressure, without professional guidance
Important Considerations
It Affects Desire, Not Performance Mechanics
Setting expectations correctly matters. PT-141 is fundamentally about desire and arousal at the brain level. It's not a substitute for PDE5 inhibitors if the issue is purely the physical mechanics of an erection, and it's not an instant on-switch — it works with your own desire pathways rather than overriding them.
The Compounded vs Approved Distinction
FDA approval applies specifically to the finished pharmaceutical product Vyleesi. Research-grade PT-141, like what's sold in the peptide market, is the same molecule (bremelanotide) but is not the approved finished product — it's sold as a research compound. This is the standard framework for peptides in our market, but it's an honest distinction worth understanding.
Quality and Sourcing
As with any peptide, quality matters. A reputable supplier provides a Certificate of Analysis confirming identity and purity — ours are available on request for every product.
A Healthcare Conversation Is Wise
Given the blood pressure effect specifically, a conversation with a qualified healthcare professional before using PT-141 is genuinely sensible — particularly to rule out any cardiovascular concerns you may not be aware of.
Common Questions
Is PT-141 the same as Viagra?
No — they work in completely different ways. Viagra and Cialis (PDE5 inhibitors) work on blood flow, helping the physical mechanics of an erection. PT-141 works on the brain, addressing sexual desire and arousal at their neurological source. They solve different problems: one is about physical mechanics, the other about desire itself. This is why they're sometimes considered complementary rather than interchangeable.
Is PT-141 FDA-approved?
Yes — bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It's one of only a handful of peptides with full FDA approval. Note that this approval applies to the specific finished product Vyleesi; research-grade PT-141 is the same molecule but is sold as a research compound rather than the approved drug.
Does PT-141 work for men?
There is Phase 2 research supporting PT-141's use in male sexual dysfunction, including in some men who don't respond well to conventional ED medications — and it was actually first studied in men. However, FDA approval for men was never formally pursued, so the evidence for men is at the Phase 2 level rather than the full approval standard that exists for women with HSDD. The mechanism is the same; the formal evidence base is simply stronger for the female indication.
How long before activity should I take it?
Per the Vyleesi label, the standard timing is at least 45 minutes before anticipated sexual activity. Because of PT-141's mechanism, effects can also last longer than its short half-life would suggest, as engaging the brain's receptors produces downstream effects that outlast the peptide itself in the bloodstream.
How often can PT-141 be used?
It's an as-needed compound, not a daily one. The Vyleesi label specifies no more than one dose in any 24-hour period, and no more than 8 doses per month. Using it more frequently than recommended increases the likelihood of side effects, including the skin pigmentation changes associated with repeated melanocortin activation.
Why does it cause nausea?
Nausea is the most common side effect, affecting around 40% of women in the clinical trials, and relates to how melanocortin receptor activation affects the body. It's usually most noticeable with the first few doses and tends to diminish with continued use. Taking it on a relatively empty stomach and starting at a conservative dose can help manage it. For most people it's mild to moderate.
Is the blood pressure effect dangerous?
For most healthy people, the temporary rise in blood pressure after dosing is modest and short-lived. However, it's the key reason PT-141 is not appropriate for anyone with uncontrolled high blood pressure or cardiovascular disease. This isn't a minor footnote — if you have any heart or blood pressure concerns, you should not use PT-141 without clearance from a healthcare professional first.
Can PT-141 cause skin darkening?
It can, with frequent or higher-than-recommended use. This traces back to PT-141's origins — it was derived from a tanning compound, and the melanocortin receptors it activates are also involved in pigmentation. At label-appropriate, as-needed frequency this is uncommon, but repeated or excessive dosing increases the likelihood of some skin darkening. It's one more reason to respect the recommended usage frequency.
Is PT-141 legal in Costa Rica?
PT-141 is sold as a research compound in Costa Rica, the same framework used in most countries with active peptide markets. While the finished product Vyleesi is FDA-approved in the US, research-grade PT-141 is sold for laboratory and research purposes and is not an approved finished drug here. See our FAQ page for more on how this works.
Questions about PT-141?
If you'd like to understand more about PT-141 or whether it fits what you're looking for, reach out. We answer every message personally and discreetly — no pressure, no judgment.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. While the finished pharmaceutical product Vyleesi (bremelanotide) is FDA-approved for a specific indication, research-grade PT-141 is not an approved finished drug and is sold as a research compound intended for laboratory and scientific study. PT-141 can cause transient increases in blood pressure and is not appropriate for people with uncontrolled hypertension or cardiovascular disease. Dosing information reflects the approved Vyleesi label and published trials; it is not an endorsement for any specific individual. Always consult a qualified healthcare professional before use, particularly regarding cardiovascular health. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- U.S. Food and Drug Administration: Vyleesi (bremelanotide) prescribing information and 2019 approval news release.
- Kingsberg, Clayton & Pfaus: "The Female Sexual Response: Bremelanotide for the Treatment of HSDD."
- RECONNECT Phase 3 Trials: Randomized controlled trials of bremelanotide in premenopausal women with HSDD.
- PubChem (NCBI): Compound summary — Bremelanotide.
- Clayton et al. (2016): Bremelanotide in female sexual dysfunction — Phase 2 dose-finding research.
- Pfaus et al.: Melanocortin agonism and central sexual motivation pathways.
- American College of Obstetricians and Gynecologists: Clinical guidance on female sexual dysfunction.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
